Badrilla                                                                              

SERCA2 Phospho-Ser38 Positive Control

Catalogue No.: C010-25           Unit Size: 100 μl; sufficient for 10 western blots when 10 μl is used

This item comes as part of a package with the anti-SERCA2 Phospho-Ser38 antibody.

Background: Due to the ambiguity surrounding the phosphorylation status of the serine residue at position 38 of SERCA2, a positive control has been produced for the anti-SERCA2 phospho-Ser38 antibody. This positive control consists of a single synthetic phospho-peptide, which corresponds to what would be the phospho-Ser38 epitope of SERCA2, covalently conjugated to a single scaffold protein (Rodriguez et al., 2004). Because of the uncertain nature of SERCA2-Ser38 phosphorylation, this positive control is required in order to confirm a phosphorylation of SERCA2-Ser38 in native samples.

Description: 100 μl of lyophilised SERCA2 phospho-Ser38 positive control protein, which is comprised of a single SERCA2 phospho-Ser38 epitope peptide covalently conjugated to a single scaffold protein.

Epitope Peptide Sequence Conjugated to Scaffold:
K₃₁LKERWGS(PO3H2)NEL₄₁

Scaffold: Concatenated and modified protein designated (I27)₅ derived from the giant muscle protein titin (Rodriguez et al., 2004).

Specificity: The positive control is specifically recognised by the anti-SERCA2a phospho-Ser38 antibody. The positive control protein also contains a (His)₆ tag, and therefore, may also be recognised by an anti-(His)₆ antibody.

Quality Control Certificate of Analysis                    Western Blot Protocol

                                                                                       QC Certificate for lot 0310-06

Related Products: Anti-SERCA2 phospho-SER38 antibody (A010-25). SERCA2 phospho-Ser38 epitope peptide (P010-25).

References:

• Laemmli, U. K. (1970): Nature 227, 680-5.

• Rodriguez, P., Jackson, W. A., and Colyer, J. (2004): J Biol Chem 279, 17111-9.

Send mail to web@badrilla.com with questions or comments about this web site.
Copyright © 2002 Badrilla
Last modified: September 19, 2007